BIOTECH ASSISTANT / FIELD NOTES

Ethris reports exploratory antiviral and exposure-response signals for nasal ETH47 in asthma

Company / institutional announcement · Ethris / GlobeNewswire

Source published: 2026-11-05 · Event / reporting date: 2026-11-05

Site published: 2026-11-05 · Updated: 2026-11-05

Explore this article with AI

This source is linked automatically. Choose a question to get started.

Ask AI ↗

Findings and limitations Industry implications Related developments

What changed

Ethris reported topline results from a randomized Phase 2a rhinovirus-challenge study involving 50 adults with asthma. A single nasal dose of ETH47, an interferon-lambda-encoding mRNA candidate, produced local expression and lower day-two viral load. Symptom improvements were described as numerical trends; exposure-response subgroup findings remain exploratory, without established clinical efficacy.

Why it may matter

Analysis: Local RNA delivery and exposure-response findings may inform dose selection, but larger controlled studies must establish clinically meaningful benefit.

The interpretation above is analysis, not a conclusion attributed to the original source.

Read the original source ↗

Prepared through Biotech Assistant’s automated research workflow. Editorial standards and corrections

mRNA / LNP Clinical Pharmacology & Model-Informed Development

Related updates

2026-11-06Moderna / ACCESS Newswire

Moderna raises 2026 revenue outlook after third-quarter growth

Moderna reported third-quarter 2026 revenue of $1.3 billion, up 29% year over year, and GAAP net income of $162 million, compared with a $200 million loss a year earlier. It raised expected full-year revenue growth to 15%–25% from up to 10%. The company attributed quarterly growth mainly to international COVID vaccine sales supported by government partnerships.

mRNA / LNP Ask AI ↗

2026-11-04Moderna / ACCESS Newswire

Moderna reports initial mRNA-2808 T-cell engager results in multiple myeloma

Moderna reported initial Phase 1/2 MyEngage findings for mRNA-2808, which encodes three T-cell engagers. Four confirmed responses occurred among 11 response-evaluable patients. Twelve patients had received treatment; Grade 3 or higher treatment-related adverse events occurred in 41.7%. These small, uncontrolled findings are preliminary and do not establish comparative benefit.

mRNA / LNP Ask AI ↗

2026-11-04Integrated DNA Technologies

IDT and Aldevron launch research-grade base and prime editing RNA tools

IDT and Aldevron launched PE Ultra prime-editor mRNA, chemically modified pegRNAs, and six ABE8e-based editor mRNAs with a parallel screening kit. The companies also described guide-design support and stocked quantities from 20 micrograms to 1 milligram. These are research-use products; the announcement does not establish clinical safety, efficacy, or approval.

mRNA / LNP Oligonucleotide Therapeutics & Delivery Ask AI ↗

Continue your research

Explore company filters, side-by-side comparisons, private bookmarks, and member discussions.

Open free member tools ↗